BNP Paribas Financial Markets Lowers Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

BNP Paribas Financial Markets trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 13.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 286,082 shares of the medical research company's stock after selling 42,836 shares during the quarter. BNP Paribas Financial Markets owned about 0.16% of IQVIA worth $67,793,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in IQV. First Foundation Advisors increased its position in shares of IQVIA by 3.8% in the second quarter. First Foundation Advisors now owns 1,161 shares of the medical research company's stock worth $245,000 after purchasing an additional 43 shares during the last quarter. Invera Wealth Advisors LLC increased its holdings in shares of IQVIA by 0.3% in the 2nd quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company's stock worth $3,183,000 after buying an additional 46 shares during the last quarter. Private Trust Co. NA raised its position in shares of IQVIA by 10.7% during the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company's stock valued at $115,000 after buying an additional 47 shares in the last quarter. Oregon Public Employees Retirement Fund grew its position in IQVIA by 0.3% in the second quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company's stock worth $3,313,000 after acquiring an additional 48 shares in the last quarter. Finally, Continuum Advisory LLC increased its stake in IQVIA by 3.3% in the second quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company's stock valued at $325,000 after acquiring an additional 49 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Up 0.1 %

Shares of IQV traded up $0.20 during trading hours on Thursday, reaching $201.43. 822,837 shares of the company traded hands, compared to its average volume of 1,177,509. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a market capitalization of $36.56 billion, a price-to-earnings ratio of 26.43, a price-to-earnings-growth ratio of 2.10 and a beta of 1.51. The company's fifty day moving average price is $219.50 and its two-hundred day moving average price is $226.40. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on IQV. Deutsche Bank Aktiengesellschaft cut their price objective on IQVIA from $270.00 to $265.00 and set a "buy" rating for the company in a report on Friday, November 1st. Argus raised shares of IQVIA to a "strong-buy" rating in a research note on Wednesday, July 31st. JPMorgan Chase & Co. lowered their price objective on shares of IQVIA from $279.00 to $240.00 and set an "overweight" rating for the company in a report on Tuesday, November 5th. Barclays decreased their target price on shares of IQVIA from $260.00 to $255.00 and set an "overweight" rating on the stock in a research report on Friday, November 1st. Finally, Leerink Partners restated an "outperform" rating and set a $248.00 price target (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Five research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $256.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.